
Morgan Stanley Maintains Sigilon Therapeutics (SGTX) Equal-Weight Recommendation
Fintel reports that on July 3, 2023, Morgan Stanley maintained coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 128.93% Upside